Kingsview Wealth Management LLC Acquires 22,586 Shares of Pfizer Inc. (NYSE:PFE)

Kingsview Wealth Management LLC raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 14.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 181,867 shares of the biopharmaceutical company's stock after acquiring an additional 22,586 shares during the period. Kingsview Wealth Management LLC's holdings in Pfizer were worth $4,609,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Providence Capital Advisors LLC boosted its holdings in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after acquiring an additional 409 shares during the last quarter. William B. Walkup & Associates Inc. boosted its holdings in shares of Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after buying an additional 454 shares during the last quarter. Members Trust Co boosted its holdings in shares of Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC boosted its holdings in shares of Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after buying an additional 472 shares during the last quarter. Finally, Bellevue Group AG boosted its holdings in shares of Pfizer by 0.3% in the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock worth $3,756,000 after buying an additional 485 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.5%

Pfizer stock traded down $0.12 during midday trading on Friday, hitting $24.46. 36,271,002 shares of the company were exchanged, compared to its average volume of 41,959,930. The company's fifty day moving average price is $24.07 and its 200-day moving average price is $24.73. The company has a market cap of $139.06 billion, a PE ratio of 17.72, a price-to-earnings-growth ratio of 0.89 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the business earned $0.82 EPS. The firm's revenue was down 7.8% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.03%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is 124.64%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Wolfe Research raised their target price on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. Redburn Atlantic reduced their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, TD Cowen reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of "Hold" and an average price target of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.